Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

Mark G. Kris, Steven M. Grunberg, Richard J. Gralla, Lorraine Baltzer, Susan A. Zaretsky, Deborah Lifsey, Leslie B. Tyson, Lisa Schmidt, William F. Hahne

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m2. Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. Emesis and adverse effects were measured for 24 hours after cisplatin. Results: All adverse effects were mild and transient including loose stools, headache, serum AST/ALT elevations, and asymptomatic prolongation of ECG intervals. Among the dose levels, no-emesis rates from 24% to 52% were observed, and the percentage of patients having zero, one, or two emetic episodes ranged from 48% to 82%. Complete control of vomiting increased as the dose was escalated to 2.4 mg/kg, but did not improve further with higher doses. Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. Antiemetic activity was seen after cisplatin. Trials comparing single infusions of dolasetron mesylate and ondansetron are under way.

Original languageEnglish (US)
Pages (from-to)1045-1049
Number of pages5
JournalJournal of Clinical Oncology
Volume12
Issue number5
StatePublished - May 1994
Externally publishedYes

Fingerprint

Serotonin Antagonists
Cisplatin
Vomiting
Antiemetics
Emetics
Ondansetron
Headache
Electrocardiography
Drug Therapy
dolasetron
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kris, M. G., Grunberg, S. M., Gralla, R. J., Baltzer, L., Zaretsky, S. A., Lifsey, D., ... Hahne, W. F. (1994). Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 12(5), 1045-1049.

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. / Kris, Mark G.; Grunberg, Steven M.; Gralla, Richard J.; Baltzer, Lorraine; Zaretsky, Susan A.; Lifsey, Deborah; Tyson, Leslie B.; Schmidt, Lisa; Hahne, William F.

In: Journal of Clinical Oncology, Vol. 12, No. 5, 05.1994, p. 1045-1049.

Research output: Contribution to journalArticle

Kris, MG, Grunberg, SM, Gralla, RJ, Baltzer, L, Zaretsky, SA, Lifsey, D, Tyson, LB, Schmidt, L & Hahne, WF 1994, 'Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin', Journal of Clinical Oncology, vol. 12, no. 5, pp. 1045-1049.
Kris, Mark G. ; Grunberg, Steven M. ; Gralla, Richard J. ; Baltzer, Lorraine ; Zaretsky, Susan A. ; Lifsey, Deborah ; Tyson, Leslie B. ; Schmidt, Lisa ; Hahne, William F. / Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 5. pp. 1045-1049.
@article{4799e631efaa4e8c8c5f6608939fb6d5,
title = "Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin",
abstract = "Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m2. Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. Emesis and adverse effects were measured for 24 hours after cisplatin. Results: All adverse effects were mild and transient including loose stools, headache, serum AST/ALT elevations, and asymptomatic prolongation of ECG intervals. Among the dose levels, no-emesis rates from 24{\%} to 52{\%} were observed, and the percentage of patients having zero, one, or two emetic episodes ranged from 48{\%} to 82{\%}. Complete control of vomiting increased as the dose was escalated to 2.4 mg/kg, but did not improve further with higher doses. Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. Antiemetic activity was seen after cisplatin. Trials comparing single infusions of dolasetron mesylate and ondansetron are under way.",
author = "Kris, {Mark G.} and Grunberg, {Steven M.} and Gralla, {Richard J.} and Lorraine Baltzer and Zaretsky, {Susan A.} and Deborah Lifsey and Tyson, {Leslie B.} and Lisa Schmidt and Hahne, {William F.}",
year = "1994",
month = "5",
language = "English (US)",
volume = "12",
pages = "1045--1049",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin

AU - Kris, Mark G.

AU - Grunberg, Steven M.

AU - Gralla, Richard J.

AU - Baltzer, Lorraine

AU - Zaretsky, Susan A.

AU - Lifsey, Deborah

AU - Tyson, Leslie B.

AU - Schmidt, Lisa

AU - Hahne, William F.

PY - 1994/5

Y1 - 1994/5

N2 - Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m2. Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. Emesis and adverse effects were measured for 24 hours after cisplatin. Results: All adverse effects were mild and transient including loose stools, headache, serum AST/ALT elevations, and asymptomatic prolongation of ECG intervals. Among the dose levels, no-emesis rates from 24% to 52% were observed, and the percentage of patients having zero, one, or two emetic episodes ranged from 48% to 82%. Complete control of vomiting increased as the dose was escalated to 2.4 mg/kg, but did not improve further with higher doses. Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. Antiemetic activity was seen after cisplatin. Trials comparing single infusions of dolasetron mesylate and ondansetron are under way.

AB - Purpose: This dose-ranging trial of intravenous dolasetron mesylate (MDL73, 147EF) was performed to determine its adverse and antiemetic effects in patients receiving cisplatin at doses ≥ 100 mg/m2. Patients and Methods: Eighty-nine patients treated with initial cisplatin received a single intravenous dose of dolasetron mesylate administered over 20 minutes beginning 30 minutes before chemotherapy. The following four dose levels were studied: 1.8, 2.4, 3.0, and 5.0 mg/kg. Emesis and adverse effects were measured for 24 hours after cisplatin. Results: All adverse effects were mild and transient including loose stools, headache, serum AST/ALT elevations, and asymptomatic prolongation of ECG intervals. Among the dose levels, no-emesis rates from 24% to 52% were observed, and the percentage of patients having zero, one, or two emetic episodes ranged from 48% to 82%. Complete control of vomiting increased as the dose was escalated to 2.4 mg/kg, but did not improve further with higher doses. Conclusion: Dolasetron mesylate can be administered safely at doses up to 5.0 mg/kg, with comparable complete protection rates and increased adverse effects at doses greater than 2.4 mg/kg. Antiemetic activity was seen after cisplatin. Trials comparing single infusions of dolasetron mesylate and ondansetron are under way.

UR - http://www.scopus.com/inward/record.url?scp=0028354474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028354474&partnerID=8YFLogxK

M3 - Article

C2 - 8164028

AN - SCOPUS:0028354474

VL - 12

SP - 1045

EP - 1049

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -